Thyroid Eye Disease (TED) Clinical Trials
Tepro Subcutaneous Trial – soon to be opened for recruiting.
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED). The first international approval outside of the U.S.
FDA expands teprotumumab indication to include any thyroid eye disease duration, activity.
Research presented at the American Society of Ophthalmic, Plastic, and Reconstructive Surgery annual meeting noted a decrease in eye muscle size for patients with TED who underwent treatment with TEPEZZA (TM), resulting in better eye movement and less double vision.
ACELYRIN is currently recruiting for a clinical study designed to evaluate lonigutamab in subjects with TED. Use this link to learn more.
- THRIVE
- Phase 3 clinical study further exploring VRDN-001 as a potential treatment for people affected by active TED
- New study website, https://ted-study.com/
- Ct.gov https://www.clinicaltrials.gov/study/NCT05176639
- Flyer Here
- THRIVE-2
- Phase 3 clinical study further exploring VRDN-001 as a potential treatment for people affected by chronic TED
- Ct.gov https://www.clinicaltrials.gov/study/NCT06021054
Immunovant is presently recruiting for a TED clinical research study. Please use this link to learn more.
See “Understanding Thyroid Eye Disease” contributed by Immunovant.
Lassen Therapeutics is currently recruiting for 2 clinical trials evaluating a novel treatment for people with TED.
LASN01-CL-2201
Phase 2 clinical trial exploring LASN01 as a potential treatment for people with active TED
https://clinicaltrials.gov/study/NCT06226545?term=lasn01&rank=1
LASN01-CL-1101
Phase 1 clinical trial further exploring LASN01 in people with active TED or idiopathic pulmonary fibrosis (IPF)
https://clinicaltrials.gov/study/NCT05331300?term=lasn01&rank=2
Tourmaline Bio is currently enrolling in the spiriTED Study – A Phase 2b clinical study investigating study drug TOUR-006 in patients with TED. Please visit – https://clinicaltrials.gov/study/NCT06088979 or https://lpcur.com/TEDCommunityOrganization for more information.
Sling Therapeutics is now recruiting participants for a Phase 2b study to evaluate a new oral treatment for TED.